Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vibegron

            Therapeutic Area: Gastroenterology Product Name: Gemtesa

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 24, 2020

            Details:

            Vibegron was very well tolerated in the study and did not lead to any worsening of IBS symptoms. Key secondary endpoint of Global Improvement Scale (GIS) showed numerical differences in favor of vibegron versus placebo, however data was not statistically significant.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apraglutide

            Therapeutic Area: Gastroenterology Product Name: FE203799

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Surveyor Capital

            Deal Size: $110.0 million Upfront Cash: Undisclosed

            Deal Type: Financing October 15, 2020

            Details:

            Proceeds will fund the Phase III program of apraglutide, a potential best-in-class GLP-2 analog, as well as global commercialization and business development activities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BBT-401

            Therapeutic Area: Gastroenterology Product Name: BBT-401

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bridge Biotherapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 15, 2020

            Details:

            BBT-401, the first-in-class Pellino-1 inhibitor for treatment of ulcerative colitis, is currently in Phase II in the US, and BBT-877, an autotaxin inhibitor to treat various fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis (IPF).